Higher CD8/regulatory T cell ratios in tumors have been shown to predict clinical benefit with anti-PD-1 therapy in patients with non—small cell lung cancer (39), hence our data support a rationale for combining RXC004 with anti-PD-1 therapies in the clinic. Here, PDCD1 is linked to lung cancer.